BBIO241018C22500
- 2.94
- 0.000.00%
BridgeBio Pharma Newsroom
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
BridgeBio Pharma Analyst Ratings
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BMO Capital Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $37
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
Cantor Fitzgerald Reiterates Overweight on BridgeBio Pharma, Maintains $70 Price Target
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $43
BridgeBio Pharma Price Target Maintained With a $43.00/Share by HC Wainwright & Co.
BridgeBio Pharma Analyst Ratings
Piper Sandler Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $46
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $42
B of A Securities Maintains Buy on BridgeBio Pharma, Maintains $42 Price Target
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $42
Buy Rating Affirmed for BridgeBio Pharma Amid Promising Clinical Trials and Strategic Decisions
J.P. Morgan Maintains BridgeBio Pharma(BBIO.US) With Buy Rating
BridgeBio Pharma Price Target Maintained With a $70.00/Share by Cantor Fitzgerald
Piper Sandler Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $46
Evercore Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $45